Braidwell LP Makes New $654,000 Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Braidwell LP purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 34,094 shares of the company's stock, valued at approximately $654,000.

Other hedge funds also recently bought and sold shares of the company. Voya Investment Management LLC lifted its stake in Viridian Therapeutics by 5.1% in the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock worth $410,000 after acquiring an additional 1,038 shares during the last quarter. Tudor Investment Corp ET AL increased its holdings in Viridian Therapeutics by 3.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock valued at $735,000 after buying an additional 1,106 shares during the last quarter. R Squared Ltd purchased a new position in Viridian Therapeutics in the fourth quarter valued at $26,000. Summit Investment Advisors Inc. lifted its holdings in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares during the last quarter. Finally, AlphaQuest LLC boosted its position in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares in the last quarter.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock traded down $0.24 during midday trading on Friday, reaching $12.54. 655,726 shares of the stock traded hands, compared to its average volume of 1,197,164. The firm has a fifty day moving average price of $13.71 and a two-hundred day moving average price of $17.49. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $27.20. The firm has a market cap of $1.02 billion, a price-to-earnings ratio of -2.91 and a beta of 0.57. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business's quarterly revenue was up .0% compared to the same quarter last year. On average, equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on VRDN shares. JMP Securities decreased their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Royal Bank of Canada dropped their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday. Needham & Company LLC decreased their target price on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group lowered their price target on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.